[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587624":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":63,"locations":71,"responsibleParty":87,"collaborators":90,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":18,"eligibilityCriteria":110,"healthyVolunteers":106,"sex":111,"minAge":112,"maxAge":18,"enrollmentInfo":113,"targetDuration":18,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":18,"overallStatus":73,"whyStopped":18,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"adaptive postoperative management group","EXPERIMENTAL","For those who don't receive neoadjuvant therapy, if the MRD testing results after surgery keep negative, postoperative adjuvant therapy will be waived.\n\nFor those who receive neoadjuvant therapy, if the efficacy reaches pathological complete response(pCR) and MRD testing results keep negative, postoperative adjuvant therapy will be waived.\n\nOtherwise, participants will receive a customized treatment plan based on Multi-disciplinary Treatment (MDT).",[13],"Other: Adaptive postoperative management based on minimal residual disease",{"label":15,"type":16,"description":17,"interventionNames":18},"standard clinical postoperative management group","NO_INTERVENTION","These participants will receive standard postoperative adjuvant therapy and routine follow-up.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Adaptive postoperative management based on minimal residual disease","participants will not receive postoperative treatment if (neoadjuvant therapy efficacy reaches pCR and) MRD results keep negative.",[9],[25,28,32,35,38,41,45,48,51,54,57,60],{"name":26,"affiliation":5,"role":27},"Kezhong Chen, MD","STUDY_CHAIR",{"name":29,"affiliation":30,"role":31},"Guangxi Wang, PhD","Peking University","STUDY_DIRECTOR",{"name":33,"affiliation":34,"role":31},"Jiatao Zhang, MD","Guangdong Provincial People's Hospital",{"name":36,"affiliation":37,"role":31},"Rong Yin, MD","Jiangsu Cancer Institute & Hospital",{"name":39,"affiliation":40,"role":31},"Ziming Li, MD","Shanghai Chest Hospital",{"name":42,"affiliation":43,"role":44},"Yintao Li, MD","Shandong Cancer Hospital and Institute","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":47,"role":44},"Zizi Zhou, MD","Shenzhen Third People's Hospital",{"name":49,"affiliation":50,"role":44},"Fang Wu, MD","Second Xiangya Hospital of Central South University",{"name":52,"affiliation":53,"role":44},"Jun Yin, MD","Shanghai Zhongshan Hospital",{"name":55,"affiliation":56,"role":44},"Yuan Cheng, MD","Peking University First Hospital",{"name":58,"affiliation":59,"role":44},"Quanfu Huang, MD","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":61,"affiliation":62,"role":44},"Xiaojun Zhu, PhD","China National Institute for Occupational Safety and Health (NIOSH\u002FCDC)",[64,68],{"name":26,"role":65,"phone":66,"phoneExt":18,"email":67},"CONTACT","+86-010-88325983","mdkzchen@163.com",{"name":69,"role":65,"phone":66,"phoneExt":18,"email":70},"Xiaoqiu Yuan","YuanXQ_pkuphxw@foxmail.com",[72],{"facility":5,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":80,"coordinates":81},"Point",[82,83],116.39723,39.9075,{"lat":83,"lon":82},[86],{"name":26,"role":65,"phone":66,"phoneExt":18,"email":67},{"type":44,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Chen KeZhong","Professor",[91,92,93,94,95,96,97,98,99,100,101],{"name":30,"class":6},{"name":34,"class":6},{"name":37,"class":6},{"name":40,"class":6},{"name":43,"class":6},{"name":47,"class":6},{"name":50,"class":6},{"name":53,"class":6},{"name":56,"class":6},{"name":59,"class":6},{"name":102,"class":103},"National Institute for Occupational Safety and Health (NIOSH\u002FCDC)","FED","100587624","liquid-biopsy-based-novel-modality-for-postoperative-management-of-lung-cancer-100587624",false,"NCT06930807","Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer","Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer","Inclusion Criteria:\n\n* Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy\n* Solid nodules \\>1 cm or ground-glass nodules \\>1.5 cm on imaging\n* No history of malignancies other than non-small cell lung cancer in the past 5 years\n* Specimens are well preserved and imaging documents are accessible.\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification)\n* Pathology results confirmed not to be non-small cell lung cancer\n* History of malignancies other than non-small cell lung cancer in the past 5 years","ALL","18 Years",{"count":114,"type":115},1000,"ESTIMATED","INTERVENTIONAL",[118],"NA","The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are:\n\n* How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer?\n* Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival?\n* Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?",[121,122,123],"Non-small Cell Lung Cancer","Minimal Residual Disease","Adaptive Treatment","2025-04-08",{"date":126,"type":127},"2025-04-16","ACTUAL",{"date":129,"type":127},"2025-03-25",{"date":131,"type":115},"2028-07-31",{"name":5,"class":6},1]